ILB-3203

ILB-3203 is a preclinical-stage bispecific antibody-drug conjugate (BsADC) being developed by Innolake Biopharm for the treatment of various oncology indications. As a bispecific ADC, the molecule is engineered to simultaneously target two distinct tumor-associated antigens or epitopes, a strategy designed to enhance tumor selectivity, facilitate internalization, and potentially overcome resistance mechanisms associated with traditional monospecific ADCs. The specific molecular targets and the cytotoxic payload utilized in ILB-3203 have not been publicly disclosed by the developer. The candidate is built upon Innolake's proprietary ADC technology platform, which focuses on optimized linkers and potent effector molecules to improve the therapeutic window for cancer patients.